Unsurprisingly, alterations in SPRY4 expression levels have been associated to a number of cancers, given that it is able to modulate both MAPK/ERK and PI3K/Akt pro-tumorigenic signaling pathways (120). The gene discussed is SPRY4; the disease is cancer.